The ONLY chance for moving the stock is the upcoming announcement of the new CEO.
If - and it's a big if - they actually hire someone with industry credibility, and he / she emphatically states that their number one priority will be getting the Forfivo sales mess straightened out - then you will see the stock pop.
Remember the original projections issued by Horst had revenue for 2014 on Forfivo at $7M - which was not at all unreasonable (in fact I thought it was too conservative). If they can actually start selling that drug and get some real revenue coming in, then this could be interesting again. Until then, it's dead for at least another 18-24 months.
News 
Market Data 
Discover 
